Consequently, the eligibility for use of pembrolizumab in cervical cancer is based on IHC staining of pathologic specimens against PD-L1, and the CPS must be ≥1 to meet the criteria for treatment with pembrolizumab as monotherapy. This evidence concerns the gene CD274 and cervical cancer.